TREX1 and cancer: Indeed, our data demonstrate that targeting TREX1 not only enhances the sensitivity of chemoresistant SCLC to chemotherapy in vitro and in vivo but also activates the cGAS-STING pathway, producing an antiviral response in cancer cells.